Shares of BOAN BIOTECH (06955.HK) surged 11.42% in pre-market trading on Thursday, following the announcement that its drug candidate BA1302 has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for two types of cancer.
According to a statement from Shandong Boan Biotechnology Co Ltd, the FDA has granted ODD to BA1302 for the treatment of Small Cell Neuroendocrine Carcinoma (SCNC) and pancreatic cancer. This significant regulatory milestone has sparked investor optimism, driving the stock's substantial pre-market rally.
The Orphan Drug Designation is a special status granted by the FDA to drugs intended to treat rare diseases or conditions. This designation provides various benefits to the developing company, including tax credits for clinical trials, exemption from user fees, and potentially seven years of market exclusivity upon approval. For BOAN BIOTECH, this development could accelerate the path to market for BA1302 and potentially boost the company's position in the competitive oncology drug market.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。